FDA notifications. New treatment approved for chronic hepatitis B.
D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D007668:Kidney / Q000187:drug effects; D063065:Organophosphonates; D014481:United States; D014486:United States Food and Drug Administration
D000998:Antiviral Agents; D063065:Organophosphonates; D000225:Adenine; C106812:adefovir dipivoxil